Retractions follow revelations of misconduct by diabetes biotech
Several months after a drug company cancelled development of a potential diabetes cure because it found evidence that a biotech they had recently acquired had committed misconduct in studies of the drug, two retractions of relevant studies have appeared. The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system … Continue reading Retractions follow revelations of misconduct by diabetes biotech